These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30784894)

  • 41. Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy.
    Andring L; Squires B; Seymour Z; Fahim D; Jacob J; Ye H; Marvin K; Grills I
    Int J Neurosci; 2023 Feb; 133(2):186-193. PubMed ID: 33685315
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bevacizumab for stereotactic radiosurgery-induced radiation necrosis in patients with non-small cell lung cancer treated with immune check-point inhibitors.
    Moore A; Yust-Katz S; Icht O; Eliyahou R; Gordon N; Cohen AY; Goldstein IM; Peled N; Seigal T; Amiel A; Dudnik E
    J Neurol Sci; 2021 Aug; 427():117556. PubMed ID: 34186494
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab emtansine increases the risk of stereotactic radiosurgery-induced radionecrosis in HER2 + breast cancer.
    Id Said B; Chen H; Jerzak KJ; Warner E; Myrehaug S; Tseng CL; Detsky J; Husain Z; Sahgal A; Soliman H
    J Neurooncol; 2022 Aug; 159(1):177-183. PubMed ID: 35715667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Laser-interstitial thermal therapy compared to craniotomy for treatment of radiation necrosis or recurrent tumor in brain metastases failing radiosurgery.
    Hong CS; Deng D; Vera A; Chiang VL
    J Neurooncol; 2019 Apr; 142(2):309-317. PubMed ID: 30656529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
    Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
    Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations.
    Mehkri Y; Windermere SA; Still MEH; Yan SC; Goutnik M; Melnick K; Doonan B; Ghiaseddin AP; Rahman M
    World Neurosurg; 2024 Jan; 181():e133-e153. PubMed ID: 37739175
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
    Choi S; Hong A; Wang T; Lo S; Chen B; Silva I; Kapoor R; Hsiao E; Fogarty GB; Carlino MS; Menzies AM; Long GV; Shivalingam BS
    Strahlenther Onkol; 2021 Dec; 197(12):1104-1112. PubMed ID: 34114045
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery.
    Stockham AL; Tievsky AL; Koyfman SA; Reddy CA; Suh JH; Vogelbaum MA; Barnett GH; Chao ST
    J Neurooncol; 2012 Aug; 109(1):149-58. PubMed ID: 22638727
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases.
    Kohutek ZA; Yamada Y; Chan TA; Brennan CW; Tabar V; Gutin PH; Yang TJ; Rosenblum MK; Ballangrud Å; Young RJ; Zhang Z; Beal K
    J Neurooncol; 2015 Oct; 125(1):149-56. PubMed ID: 26307446
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Imaging changes over 18 months following stereotactic radiosurgery for brain metastases: both late radiation necrosis and tumor progression can occur.
    Fujimoto D; von Eyben R; Gibbs IC; Chang SD; Li G; Harsh GR; Hancock S; Fischbein N; Soltys SG
    J Neurooncol; 2018 Jan; 136(1):207-212. PubMed ID: 29098569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiation necrosis and therapeutic outcomes in patients treated with linear accelerator-based hypofractionated stereotactic radiosurgery for intact intracranial metastases.
    Zhang Q; Hamilton D; Conway P; Xie SJ; Haghighi N; Lasocki A
    J Med Imaging Radiat Oncol; 2023 Apr; 67(3):308-319. PubMed ID: 36847751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.
    Kirkpatrick JP; Wang Z; Sampson JH; McSherry F; Herndon JE; Allen KJ; Duffy E; Hoang JK; Chang Z; Yoo DS; Kelsey CR; Yin FF
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):100-8. PubMed ID: 25442342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab reduces cerebral radiation necrosis due to stereotactic radiotherapy in non-small cell lung cancer patients with brain metastases: an inverse probability of treatment weighting analysis.
    Zhang J; Yu J; Yang D; Jiang L; Dong X; Liu Z; Yu R; Yu H; Shi A
    Front Immunol; 2024; 15():1399613. PubMed ID: 39257576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic radiotherapy following surgery for brain metastasis: Predictive factors for local control and radionecrosis.
    Doré M; Martin S; Delpon G; Clément K; Campion L; Thillays F
    Cancer Radiother; 2017 Feb; 21(1):4-9. PubMed ID: 27955888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Stereotactic radiosurgery using the Leksell Gamma Knife Perfexion unit in the management of patients with 10 or more brain metastases.
    Grandhi R; Kondziolka D; Panczykowski D; Monaco EA; Kano H; Niranjan A; Flickinger JC; Lunsford LD
    J Neurosurg; 2012 Aug; 117(2):237-45. PubMed ID: 22631694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Stereotactic Radiation Therapy for Renal Cell Carcinoma Brain Metastases in the Tyrosine Kinase Inhibitors Era: Outcomes of 120 Patients.
    Klausner G; Troussier I; Biau J; Jacob J; Schernberg A; Canova CH; Simon JM; Borius PY; Malouf G; Spano JP; Roupret M; Cornu P; Mazeron JJ; Valéry C; Feuvret L; Maingon P
    Clin Genitourin Cancer; 2019 Jun; 17(3):191-200. PubMed ID: 30926219
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage stereotactic radiosurgery with adjuvant use of bevacizumab for heavily treated recurrent brain metastases: a preliminary report.
    Yomo S; Hayashi M
    J Neurooncol; 2016 Mar; 127(1):119-26. PubMed ID: 26619997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bevacizumab as a treatment for radiation necrosis following stereotactic radiosurgery for brain metastases: clinical and radiation dosimetric impacts.
    Li J; He J; Cai L; Lai M; Hu Q; Ren C; Wen L; Wang J; Zhou J; Zhou Z; Li S; Ye M; Shan C; Chen L; Zhou C
    Ann Palliat Med; 2021 Feb; 10(2):2018-2026. PubMed ID: 33549015
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS.
    Stockham AL; Ahluwalia M; Reddy CA; Suh JH; Kumar A; Vogelbaum MA; Barnett GH; Murphy ES; Chao ST
    J Neurooncol; 2013 Dec; 115(3):469-75. PubMed ID: 24045970
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions After Stereotactic Radiosurgery for Brain Metastasis.
    Sharma M; Jia X; Ahluwalia M; Barnett GH; Vogelbaum MA; Chao ST; Suh JH; Murphy ES; Yu JS; Angelov L; Mohammadi AM
    World Neurosurg; 2017 Oct; 106():666-675. PubMed ID: 28735139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.